The high cost of prescription drugs in the United States origins and prospects for reform

JAMA - Journal of the American Medical Association

Volumn 316, Issue 8, 2016, Pages 858-871

  Kesselheim, Aaron S ^a   Avorn, Jerry ^a   Sarpatwari, Ameet ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALIROCUMAB; ECULIZUMAB; ESOMEPRAZOLE; FILGRASTIM; FLUTICASONE PROPIONATE PLUS SALMETEROL; GENERIC DRUG; INSULIN GLARGINE; OMEPRAZOLE; RECOMBINANT ERYTHROPOIETIN; ROSUVASTATIN; SIMVASTATIN; SITAGLIPTIN; SOFOSBUVIR; TRASTUZUMAB; PRESCRIPTION DRUG;

CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES; COST CONTROL; DRUG APPROVAL; ECONOMIC ASPECT; ECONOMICS; INTERPERSONAL COMMUNICATION; LEGISLATION AND JURISPRUDENCE; PATENT; REIMBURSEMENT; RESEARCH; TRENDS;

COST CONTROL; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUGS, GENERIC; ECONOMIC COMPETITION; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NEGOTIATING; PATENTS AS TOPIC; PRESCRIPTION DRUGS; RESEARCH; UNITED STATES;

EID: 84985864585     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.11237     Document Type: Review

References (177)

1. Walker J. Drugmakers' pricing power remains strong.Wall Street Journal. http://www.wsj.com /articles/drugmakers-pricing-power-remains -strong-1468488601. Published July 14, 2016. Accessed July 14, 2016.
2. IMS Institute for Healthcare Informatics. Medicine use and spending in the US: a review of 2015 and outlook to 2020. https://morningconsult .com/wp-content/uploads/2016/04/IMS-Institute -US-Drug-Spending-2015.pdf. Published April 2016. Accessed August 7, 2016.
3. Keehan SP, Cuckler GA, Sisko AM, et al. National health expenditure projections, 2014-24: spending growth faster than recent trends. Health Aff (Millwood). 2015;34(8):1407-1417.
4. Observations on trends in prescription drug spending. ASPE Issue Brief. https://aspe.hhs.gov /sites/default/files/pdf/187586/Drugspending.pdf. Published March 8, 2016. Accessed July 13, 2016.
5. Altman D. Prescription drug's sizeable share of health spending.Washington Post. http://blogs.wsj .com/washwire/2015/12/13/prescription-drugs -sizable-share-of-health-spending/. Published December 13, 2015. Accessed July 13, 2016.
6. Department of Health and Human Services. Health, United States, 2015. http://www.cdc.gov /nchs/data/hus/hus15.pdf#094. Published May 2016. Accessed July 13, 2016.
7. Quon BS, Firszt R, Eisenberg MJ. A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major US drug chain pharmacies. Ann Intern Med. 2005;143 (6):397-403.
8. Organisation for Economic Co-operation and Development. Health at a Glance 2015: OECD Indicators. Paris, France: OECD Publishing, 2015.
9. Hirschler B. Exclusive-transatlantic divide: how US pays three times more for drugs. Reuters. http: //www.reuters.com/article/us-pharmaceuticals -usa-comparison-idUSKCN0S61KU20151012. Published October 12, 2015. Accessed July 13, 2016.
10. Langreth R, Migliozzi B, Gokhale K. The US pays a lot more for top drugs than other countries. Bloomberg Business. http://www.bloomberg.com /graphics/2015-drug-prices/. Published December 18, 2015. Accessed July 13, 2016.
11. Kanavos P, Ferrario A, Vandoros S, Anderson GF. Higher US branded drug prices and spending compared to other countriesmay stem partly from quick uptake of new drugs. Health Aff (Millwood). 2013;32(4):753-761.
12. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
13. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407-419.
14. Menges Group. Analysis of Medicaid costs and usage of selected specialty medications-Sovaldi, Harvoni, and Kalydeco. https://www .themengesgroup.com/presentation/april-2015-medicaid-data-on-sovaldi-harvoni-and-kalydeco .pdf. Published April 2015. Accessed July 13, 2016.
15. Generic Pharmaceutical Association. Generic drug savings in the US. http://www.gphaonline.org /media/wysiwyg/PDF/GPhA-Savings-Report-2015 .pdf. Published November 3, 2015. Accessed July 13, 2016.
16. Express Scripts. The 2015 drug trend report. http://lab.express-scripts.com/lab/drug-trend -report. Published March 2015. Accessed July 31, 2016.
17. Bureau of Labor Statistics. Databases, tables and calculators by subject. http://data.bls.gov /timeseries/CUUR0000SAM?output-view=pct-12mths. Published January 5, 2016. Accessed July 13, 2016.
18. Fisher LM. Company news; new enzyme by Genzyme is approved. New York Times. http://www .nytimes.com/1994/05/25/business/company -news-new-enzyme-by-genzyme-is-approved.html. Published May 25, 1994. Accessed July 13, 2016.
19. Weisman R. New Genzyme pill will cost patients 310,250. Boston Globe. https://www.bostonglobe .com/business/2014/09/02/new-genzyme-pill -treat-rare-gaucher-disease-will-cost-patients-year /5thkIb587nKi7zRAb9GgxM/story.html. Published September 2, 2014. Accessed July 13, 2016.
20. Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014. JAMA Oncol. 2016;2(7):960-961.
21. Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA. 2016;315(13): 1400-1402.
22. Pollack A. Drug goes from 13.50 a tablet to 750, overnight. New York Times. http://www .nytimes.com/2015/09/21/business/a-huge -overnight-increase-in-a-drugs-price-raisesprotests. html?-r=0. Published September 20, 2015. Accessed July 13, 2016.
23. O'Brien E. Why drug prices remain insanely high and 6 things you can do to save. Market Watch. http://www.marketwatch.com/story/six-tips-for -fighting-rising-prescription-drug-costs-2015-09-15. Published September 21, 2015. Accessed July 13, 2016.
24. Stabile M, Thomson S, Allin S, et al. Health care cost containment strategies used in four other high-income countries hold lessons for the United States. Health Aff (Millwood). 2013;32(4): 643-652.
25. Chalkidou K; Commonwealth Fund. Comparative effectiveness review within the UK's National Institute for Health and Clinical Excellence. http://www.commonwealthfund.org/~/media/Files /Publications/Issue%20Brief/2009/Jul/Chalkidou /1296-Chalkidou-UK-CER-issue-brief-717.pdf. Published July 2009. Accessed July 13, 2016.
26. Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39-47.
27. Directorate-General for Internal Policies. Differences in costs of an access to pharmaceutical products in the EU. 2011. http://www.europarl .europa.eu/RegData/etudes/etudes/join/2011 /451481/IPOL-ENVI-ET(2011)451481-EN.pdf. Accessed July 13, 2016.
28. Reinhardt U. Probing our moral values in health care: the pricing of specialty drugs. JAMA. 2015;314 (10):981-982.
29. Food and Drug Administration. 21 CFR 314.108: code of federal regulations title 21.
30. US Government Publishing Office. 42 USC-+ - 262(k)(7)(A): regulation of biological products.
31. USC 154(a)(2): contents and term of patent: provisional rights.
32. USC 102, 103: conditions for patentability: novelty and non-obvious subject matter.
33. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89 (2):183-188.
34. US Government Publishing Office. 35 USC 156: extension of patient term.
35. Wharton GT, Murphy MD, Avant D, et al. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy. Pediatrics. 2014;134(2): e512-e518.
36. Food and Drug Administration. Pediatric exclusivity granted. http://www.fda.gov/downloads /Drugs/DevelopmentApprovalProcess /DevelopmentResources/UCM505429.pdf. Published May 2016. Accessed July 13, 2016.
37. Wang B, Liu J, Kesselheim AS. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern Med. 2015;175(4):635-637.
38. Grabowski H, Long G, Mortimer R, Boyo A. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;20:1-9.
39. Lichtenberg FR, Philipson T. The dual effects of intellectual property regulations: within- and between-patent competition in the US pharmaceuticals industry. J Law Econ. 2002;45: 643-672.
40. Loftus P. Special sale price: docs divided over discount on Abb Vie hepatitis C drug. Wall Street Journal. http://blogs.wsj.com/pharmalot/2014/12 /22/special-sale-price-docs-divided-over-discount -on-abbvie-hepatitis-c-drug/. Published December 22, 2014. Accessed July 13, 2016.
41. Ramsey SD. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs. Health Aff (Millwood). 2015;34(4):571-575.
42. Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6): 1493-1505.
43. Consumer Reports. Knowing when prescription prices are high and how to avoid overspending. http://www.consumerreports.org /cro/2012/11/where-high-drug-costs-hide/index .htm. Published November 2012. Accessed July 13, 2016.
44. Reinke T; Managed Care. Free statins disrupt pharmacy benefits plans. http://www .managedcaremag.com/archives/2012/11/free -statins-disrupt-pharmacy-benefit-plans. Published November 2012. Accessed July 13, 2016.
45. Azoulay P. Do pharmaceutical sales respond to scientific evidence? J Econ Manage Strategy. 2002; 11(4):551-594.
46. Bureau of Consumer Protection. Staff Report to the Federal Trade Commission. Washington, DC: US Government Printing Office; 1979.
47. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):e283.
48. Federal Trade Commission. Pay-for-delay: how drug company pay-offs cost consumers billions. https://www.ftc.gov/sites/default/files/documents /reports/pay-delay-how-drug-company-pay-offs -cost-consumers-billions-federal-trade -commission-staff-study/100112payfordelayrpt.pdf. Published January 2010. Accessed July 13, 2016.
49. Food and Drug Administration. Generic competition and drug prices. http://www.fda.gov /AboutFDA/CentersOffices /OfficeofMedicalProductsandTobacco/CDER /ucm129385.htm. Updated May 13, 2015. Accessed July 13, 2016.
50. Government Accountability Office. Drug pricing: research on savings from generic drug use. http://www.gao.gov/assets/590/588064.pdf. Published January 31, 2012. Accessed July 13, 2016.
51. Silverman E. Reckitt's Suboxone strategy is really about patients or profits? Forbes. http://www .forbes.com/sites/edsilverman/2012/10/12 /reckitts-suboxone-strategy-is-really-about -patients-or-profits/. Published October 12, 2012. Accessed July 13, 2016.
52. Kapczynski A, Park C, Sampat B. Polymorphs and prodrugs and salts (ohmy!): an empirical analysis of "secondary" pharmaceutical patents. PLoS One. 2012;7(12):e49470.
53. Pollack A. Makers of Humira and Enbrel using new drug product patents to delay generic versions. New York Times. http://www.nytimes.com /2016/07/16/business/makers-of-humira-and -enbrel-using-new-drug-patents-to-delay-generic -versions.html. Published July 15, 2016. Accessed July 15, 2016.
54. Community Catalyst. In re Nexium consumer/payor advertising litigation: consolidated class action complaint. http://www .communitycatalyst.org/pal-docs/Nexium-DE.pdf. Published May 27, 2005. Accessed July 13, 2016.
55. Federal Trade Commission. Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement and Modernization Act of 2003. https://www.ftc.gov /reports/agreements-filed-federal-trade -commission-under-medicare-prescription-drug -improvement. Published January 2013. Accessed July 13, 2016.
56. Hemphill CS. Paying for delay: pharmaceutical patent settlement as a regulatory design problem. New York Univ Law Rev. 2006;81:1553-1623.
57. Woodcock J, WosinskaM. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther. 2013;93(2): 170-176.
58. Woodcock J. Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA). Testimony before the Committee on Health, Education, Labor and Pensions United States Senate. January 28, 2016. http://www.help.senate .gov/imo/media/doc/Woodcock5.pdf. Accessed July 15, 2016.
59. Sarpatwari A, Avorn J, Kesselheim AS. Using a drug-safety tool to prevent competition. N Engl J Med. 2014;370(16):1476-1478.
60. US Government Publishing Office. Pub. L. No. 111-148, 124 Stat. 119 (2010): Patient Protection and Affordable Care Act.
61. Sarpatwari A, Kesselheim AS. The case for reforming drug naming: should brand name trademark protection expire upon generic entry? PLoS Med. 2016;13(2):e1001955.
62. Shrank WH, Choudhry NK, Agnew-Blais J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood). 2010;29(7):1383-1390.
63. Shrank WH, Liberman JN, Fischer MA, et al. The consequences of requesting "dispense as written. " Am J Med. 2011;124(4):309-317.
64. Kesselheim AS, Franklin JM, Kim SC, Seeger JD, Solomon DH. Reductions in use of colchicine after FDA enforcement of market exclusivity in a commercially insured population. J Gen Intern Med. 2015;30(11):1633-1638.
65. Jena AB, Ho O, Goldman DP, Karaca-Mandic P. The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket costs and use of albuterol inhalers among individuals with asthma. JAMA Intern Med. 2015;175(7):1171-1179.
66. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297 (5):480-488.
67. Centers for Medicare and Medicaid Services. On its 50th anniversary, more than 55 million Americans covered by Medicare. https://www.cms .gov/Newsroom/MediaReleaseDatabase/Press -releases/2015-Press-releases-items/2015-07-28 .html. Published July 28, 2015. Accessed July 13, 2016.
68. Henry J Kaiser Family Foundation. Total monthly Medicaid and CHIP enrollment. http://kff .org/health-reform/state-indicator/total-monthly -medicaid-and-chip-enrollment/. Published June 30, 2016. Accessed July 13, 2016.
69. Cohen RA, Martinez ME, Zammitti EP; National Center for Health Statistics. Early release of selected estimates based on data from the National Health Interview Survey, 2015. http://www.cdc.gov /nchs/nhis/releases/released201605.htm. Published May 24, 2016. Accessed July 13, 2016.
70. The short answer: pharmacy-benefit managers.Wall Street Journal. http://blogs.wsj.com /briefly/2015/03/30/pharmacy-benefit-managers -the-short-answer/. Published March 30, 2015. Accessed July 13, 2016.
71. Obama B. United States health care reform: progress to date and next steps. JAMA. doi:10.1001/jama.2016.9797.
72. California Health Care Foundation. US health care spending: who pays? http://www.chcf.org/publications/2015/12/data-viz-hcc-national. Updated December 2015. Accessed July 13, 2016.
73. Oliver TR, Lee PR, Lipton HL. A political history of medicare and prescription drug coverage. Milbank Q. 2004;82(2):283-354.
74. US Government Publishing Office. 42 USC. 1395: health insurance for aged and disabled.
75. Medicaid.gov. Medicaid drug rebate program. https://www.medicaid.gov/medicaid-chip -program-information/by-topics/benefits /prescription-drugs/medicaid-drug-rebate-program .html. Updated June 16, 2016. Accessed July 13, 2016.
76. Shajarizadeh A, Hollis A. Price-cap regulation, uncertainty and the price evolution of new pharmaceuticals. Health Econ. 2015;24(8):966-977.
77. Chokshi DA. Improving health care for veterans- A watershed moment for the VA. N Engl J Med. 2014;371(4):297-299.
78. Hayes JM, Walczak H, Prochazka A. Comparison of drug regimen costs between the Medicare prescription discount program and other purchasing systems. JAMA. 2005;294(4): 427-428.
79. US Congressional Budget Office. Prices for Brand-Name Drugs Under Selected Federal Programs. US Congressional Budget Office; 2005.
80. US Department of Veterans Affairs; Health Economics Resource Center. Determining the cost of pharmaceuticals for a cost-effectiveness analysis. http://www.herc.research.va.gov/include/page.asp ?id=pharmaceutical-costs. Accessed July 13, 2016.
81. Frakt AB, Pizer SD, Hendricks AM. Controlling prescription drug costs: regulation and the role of interest groups in Medicare and the Veterans Health Administration. J Health Polit Policy Law. 2008;33(6):1079-1106.
82. Pollack A. AbbVie deal heralds changed landscape for hepatitis drugs. New York Times. http: //www.nytimes.com/2014/12/22/business /pharmacy-deal-heralds-changed-landscape-for -hepatitis-drugs.html. Published December 22, 2014. Accessed July 13, 2016.
83. Martinez B. Merck kills Medco IPO plan, will spin off unit to holders. Wall Street Journal. http: //www.wsj.com/articles/SB105103638029142500. Updated April 23, 2003. Accessed July 13, 2016.
84. Moses H III, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174-189.
85. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R and D costs. J Health Econ. 2016;47: 20-33.
86. Avorn J. The 2.6 billion pill-methodologic and policy considerations. N Engl J Med. 2015;372 (20):1877-1879.
87. DiMasi JA, Grabowski HG, Hansen RW. The cost of drug development. N Engl J Med. 2015;372(20): 1972.
88. Kesselheim AS, Tan YT, Avorn J. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff (Millwood). 2015;34(2):286-293.
89. Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov. 2010;9(11):867-882.
90. Burns LR, Housman MG, Robinson CA. Market entry and exit by biotech and device companies funded by venture capital. Health Aff (Millwood). 2009;28(1):w76-w86.
91. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348.
92. Keyhani S, Wang S, Hebert P, Carpenter D, Anderson G. US pharmaceutical innovation in an international context. Am J Public Health. 2010;100 (6):1075-1080.
93. Keyhani S, Diener-West M, Powe N. Are development times for pharmaceuticals increasing or decreasing? Health Aff (Millwood). 2006;25(2): 461-468.
94. Rockoff JD. How Pfizer set the cost of its new drug at 9,850 a month. Wall Street Journal. http: //www.wsj.com/articles/the-art-of-setting-a-drug -price-1449628081. Published December 9, 2015. Accessed July 13, 2016.
95. Alpern JD, Stauffer WM, Kesselheim AS. High-cost generic drugs-implications for patients and policymakers. N Engl J Med. 2014;371(20): 1859-1862.
96. US House Committee on Oversight and Government Reform. Documents obtained by committee from Turing Pharmaceuticals. http: //democrats.oversight.house.gov/sites/democrats .oversight.house.gov/files/documents/Memo %20on%20Turing%20Documents.pdf. Accessed February 5, 2016.
97. Sachs J. The drug that is bankrupting America. Huffington Post. http://www.huffingtonpost.com /jeffrey-sachs/the-drug-that-is-bankrupt-b-6692340.html. Published February 16, 2015. Accessed July 13, 2016.
98. Pollack A. Sales of Sovaldi, new Gilead hepatitis C drug soar to 10.3 billion. New York Times. http: //www.nytimes.com/2015/02/04/business/sales -of-sovaldi-new-gilead-hepatitis-c-drug-soar-to-10 -3-billion.html. Published February 3, 2015. Accessed July 13, 2016.
99. United States Senate Committee on Finance. The price of Sovaldi and its impact on the US health care system. http://www.finance.senate.gov/imo /media/doc/1%20The%20Price%20of %20Sovaldi%20and%20Its%20Impact%20on %20the%20US%20Health%20Care%20System %20(Full%20Report).pdf. Published December 2015. Accessed July 13, 2016.
100. Jung K, Feldman R, McBean AM. Nonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D. Health Serv Res. 2014;49(3):910-928
101. Fung V, Reed M, Price M, et al. Responses to Medicare drug costs among near-poor versus subsidized beneficiaries. Health Serv Res. 2013;48 (5):1653-1668.
102. Henry J Kaiser Family Foundation. 2015 Employer health benefits survey. http://kff.org /report-section/ehbs-2015-summary-of-findings/. Published September 22, 2015. Accessed July 13, 2016.
103. Claxton G, RaeM, Panchal N, et al. Health benefits in 2015: stable trends in the employer market. Health Aff (Millwood). 2015;34(10): 1779-1788.
104. Lee TH, Emanuel EJ. Tier 4 drugs and the fraying of the social compact. N Engl J Med. 2008; 359(4):333-335.
105. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359.
106. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
107. DiJulio B, Firth J, Brodie M. Kaiser health tracking poll: August 2015. http://kff.org/health -costs/poll-finding/kaiser-health-tracking-poll -august-2015/. Published August 20, 2015. Accessed July 13, 2016.
108. Gagne JJ, Choudhry NK, Kesselheim AS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400-407.
109. IMS Institute for Healthcare Informatics. Avoidable costs in US healthcare. http://www .imshealth.com/de-AT/thought-leadership/ims -institute/reports/avoidable-costs. Published June 2013. Accessed July 13, 2016.
110. Starner CI, Alexander GC, Bowen K, Qiu Y, Wickersham PJ, Gleason PP. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums. Health Aff (Millwood). 2014;33(10):1761-1769.
111. Ross JS, Kesselheim AS. Prescription-drug coupons-no such thing as a free lunch. N Engl J Med. 2013;369(13):1188-1189.
112. Leonard K. Budget breakers: the increasing cost of prescription drugs makes both families and governments go into the red. US News and World Report. http://www.usnews.com/news/the-report /articles/2015/09/24/expensive-drugs-a-drag-on -consumers-and-government. Published Sept 24, 2015. Accessed August 4, 2016.
113. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215-223.
114. Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med. 2015;163 (3):226-228.
115. Kantarjian H, Rajkumar SV.Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc. 2015;90(4): 500-504.
116. Daniel H; Health and Public Policy Committee of the American College of Physicians. Stemming the escalating cost of prescription drugs: a position paper of the American College of Physicians. Ann Intern Med. doi:10.7326/M15-2768.
117. Association for Molecular Pathology v Myriad Genetics, Inc, 133 SCt 2107 (2013). 118. KSR International Co. v Teleflex, Inc, 127 SCt 1727 (2007).
118. Mayo v Prometheus, 132 SCt 1289 (2012).
119. Alice Corp. v CLS Bank International, 134 SCt 2347 (2014).
120. Gabble R, Kohler JC. To patent or not to patent? the case of Novartis' cancer drug Glivec in India. Global Health. 2014;10:3.
121. FTC v Actavis, 133 S Ct 2223 (2013).
122. Tucker RJ. Status of pay-for-delay cases nearly two years after Actavis-'it ain't over 'til it's over.' Mondaq. http://www.mondaq.com/unitedstates/x /398342/Antitrust+Competition/Status+of+ PayforDelay+Cases+Nearly+Two+Years+After+ Actavis+It+aint+over+til+its+over. Published May 19, 2015. Accessed July 13, 2016.
123. New York v Actavis, 787 F3d 638 (2d Cir 2015).
124. Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services. Some observations related to the generic drug market. https://aspe.hhs.gov/sites/default /files/pdf/139331/ib-GenericMarket.pdf. Published May 6, 2015. Accessed July 13, 2016.
125. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R and D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.
126. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7): 673-681.
127. Niederdeppe J, Byrne S, Avery RJ, Cantor J. Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use. J Gen Intern Med. 2013;28(7):886-893.
128. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? a survey in primary care environments with and without legal DTCA. CMAJ. 2003;169(5): 405-412.
129. Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements about medications'loosening the rules. N Engl J Med. 2015;373(10):967-973.
130. Wiske CP, Ogbechie OA, Schulman KA. Options to promote competitive generics markets in the United States. JAMA. 2015;314(20):2129-2130.
131. US Senate. CREATES Act of 2016 (S 3056). 14 Jun 2016. https://www.congress.gov/bill/114th -congress/senate-bill/3056/text. Accessed July 13, 2016.
132. Greene JA, Anderson G, Sharfstein JM. Role of the FDA in affordability of off-patent pharmaceuticals. JAMA. 2016;315(5):461-462.
133. Gastala NM, Wingrove P, Gaglioti A, Petterson S, Bazemore A. Medicare Part D: patients bear the cost of 'me too' brand-name drugs. Health Aff (Millwood). 2016;35(7):1237-1240.
134. Megerlin F, Lopert R, Taymor K, Trouvin JH. Biosimilars and the European experience: implications for the United States. Health Aff (Millwood). 2013;32(10):1803-1810.
135. Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther. 2010;87(2):157-159.
136. Hirschler B, Shields M. Novartis launches first US 'biosimilar' drug at 15 percent discount. Reuters. http://www.reuters.com/article/us-novartis-drug -idUSKCN0R30C220150903. Published September 3, 2015. Accessed July 13, 2016.
137. European Medicines Agency. European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar-search.jsp&mid=WC0b01ac058001d125. Accessed July 31, 2016.
138. IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets. http://www.imshealth.com/files /web/IMSH%20Institute/Healthcare%20Briefs/Assessing-biosimilar-uptake-and-competition-in -European-markets.pdf. Published October 2014. Accessed July 13, 2016.
139. Anell A. The Swedish health care system. Commonwealth Fund. http://www .commonwealthfund.org/~/media/files/resources /2008/health-care-system-profiles/sweden -country-profile-2008-pdf.pdf. Published February 2008. Accessed July 13, 2016.
140. Center for Responsive Politics. Lobbying: top industries. https://www.opensecrets.org/lobby/top.php&showYear=a&indexType=i. Accessed July 13, 2016.
141. Outterson K, Kesselheim AS. How Medicare could get better prices on prescription drugs. Health Aff (Millwood). 2009;28(5):w832-w841.
142. Conti RM, Rosenthal MB. Pharmaceutical policy reform-balancing affordability with incentives for innovation. N Engl J Med. 2016;374 (8):703-706.
143. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16):1629-1630.
144. Mailankody S, Prasad V. Implications of proposed Medicare reforms to counteract high drug prices. JAMA. 2016;316(3):271-272.
145. Brekke KR, Canta C, Straume OR. Reference pricing with endogenous generic entry. J Health Econ. 2016;(16):30021-30022.
146. Hawkins N, Scott DA. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word. Health Econ. 2011;20(6):688-698.
147. O'Donnell JC, Pham SV, Pashos CL, et al. Health technology assessment in evidence-based health care reimbursement decisions around the world: an overview. Value Health. 2009;12(suppl 2): S1-S5.
148. Neumann PJ, Cohen JT. Measuring the value of prescription drugs. N Engl J Med. 2015;373(27): 2595-2597.
149. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307(15):1583-1584.
150. Sorenson C, Gusmano MK, Oliver A. The politics of comparative effectiveness research: lessons from recent history. J Health Polit Policy Law. 2014;39(1):139-170.
151. Schulte F. Obamacare research institute plans to spend 3.5 billion, but critics question its worth. Center for Public Integrity. https://www .publicintegrity.org/2015/08/04/17762 /obamacare-research-institute-plans-spend-35 -billion-critics-question-its-worth. Published August 4, 2015. Accessed July 13, 2016.
152. Bach PB, Pearson SD. Payer and policy maker steps to support value-based pricing for drugs. JAMA. 2015;314(23):2503-2504.
153. Medical Letter. About us. http://secure .medicalletter.org/aboutus. Accessed July 13, 2016.
154. Independent Drug Information Service. Alosa Foundation. http://www.alosafoundation.org /independent-drug-information-service/. Accessed July 13, 2016.
155. Neumann PJ. Emerging lessons from the Drug Effectiveness Review Project. Health Aff (Millwood). 2006;25(4):W262-W271.
156. Findlay SD. Bringing the DERP to consumers: Consumer Reports Best Buy Drugs. Health Aff (Millwood). 2006;25(4):W283-W286.
157. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs: NBER working paper 20867. J Econ Perspectives. 2015;29 (1):139-162.
158. Mailankody S, Prasad V. Five years of cancer drug approvals. JAMA Oncol. 2015;1(4): 539-540.
159. Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2016;2(1):19-21.
160. Schnipper LE, Davidson NE,Wollins DS, et al; American Society of Clinical Oncology. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23): 2563-2577.
161. Chandra A, Shafrin J, Dhawan R. Utility of cancer value frameworks for patients, payers, and physicians. JAMA. 2016;315(19):2069-2070.
162. LaMattina J. 'Pay for performance' drug plans could impact biopharma's R and D priorities. Forbes.com. http://www.forbes.com/sites /johnlamattina/2016/05/18/pay-for-performance -drug-plans-could-impact-biopharmas-rd-priorities /#7d98d0513c68. Published May 18, 2016. Accessed August 4, 2016.
163. Hollis A. Sustainable financing of innovative therapies: a review of approaches. Pharmacoeconomics. 2016. doi:10.1007/s40273 -016-0416-x.
164. US Government Publishing Office. 28 USC 1498: judiciary and judicial procedure.
165. Kapczynski A, Kesselheim AS. 'Government patent use': a legal approach to reducing drug spending. Health Aff (Millwood). 2016;35(5): 791-797.
166. Arno PS, Davis MH. Why don't we enforce existing drug price controls? the unrecognized and unenforced reasonable pricing requirements imposed upon patents deriving in whole or in part from federally funded research. Tulane Law Rev. 2001;75:631-693.
167. Love J. Non-voluntary use of patents for drugs to treat the hepatitis C virus in the United States: mechanisms available to the federal government, state governments, and private actors. Knowledge Ecology International. http://keionline.org/sites /default/files/Non-voluntary-use-HCV-patents-USA .pdf. Published July 18, 2014. Accessed July 13, 2016.
168. Treasure CL, Avorn J, Kesselheim AS. Do march-in rights ensure access to medical products arising from federally funded research? Milbank Q. 2015;93(4):761-787.
169. Ubel PA, Abernethy AP, Zafar SY. Full disclosure'out-of-pocket costs as side effects. N Engl J Med. 2013;369(16):1484-1486.
170. Fischer MA, Avorn J. Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings. Health Aff (Millwood). 2012;31(10):2206-2212.
171. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;4(4):CD000409.
172. Where is academic detailing used? http://www .alosafoundation.org/academic-detailing/where -academic-detailing-used/. Accessed July 13, 2016.
173. Newcomer LN. Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Aff (Millwood). 2012;31(4):780-785.
174. Robinson JC. Value and payment for oncology in the United States. Ann Pharm Fr. 2013;71(5): 285-290.
175. Jacobs DB, Sommers BD. Using drugs to discriminate-adverse selection in the insurance marketplace. N Engl J Med. 2015;372(5): 399-402.
176. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.
177. Choudhry NK, Avorn J, Glynn RJ, et al; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications aftermyocardial infarction. N Engl J Med. 2011;365(22):2088-2097.